Revolution Medicines Inc.

Revolution Medicines, Inc. is a clinical-stage biopharmaceutical company that specializes in developing targeted therapies for cancers driven by RAS and related oncogenic pathways. Founded in 2014, the company focuses on addressing some of the most difficult-to-treat cancers by designing small-molecule drugs that selectively inhibit mutant proteins involved in tumor growth and progression. Revolution Medicines’ research pipeline includes therapies aimed at treating pancreatic cancer, lung cancer, and other solid tumors associated with RAS mutations. The company utilizes advanced medicinal chemistry, structural biology, and translational science to create precision oncology treatments. With a strong emphasis on innovation and unmet medical needs, Revolution Medicines is committed to advancing next-generation cancer therapies and improving outcomes for patients with limited treatment options.